Cargando…
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer
BACKGROUND: Histone acetylation/deacetylase process is one of the most studied epigenetic modifications. Histone deacetylase inhibitors (HDACis) have shown clinical benefits in haematological malignancies but failed in solid tumours due to the lack of biomarker-driven stratification. METHODS: We per...
Autores principales: | Yang, Haitang, Sun, Beibei, Xu, Ke, He, Yunfei, Zhang, Tuo, Hall, Sean R R, Tan, Swee T., Schmid, Ralph A., Peng, Ren-Wang, Hu, Guohong, Yao, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264109/ https://www.ncbi.nlm.nih.gov/pubmed/34224975 http://dx.doi.org/10.1016/j.ebiom.2021.103457 |
Ejemplares similares
-
Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma
por: Djokovic, Nemanja, et al.
Publicado: (2023) -
NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2021) -
Pharmaco-prosthodontics revisited
por: Jagadeeshwaran, A. R., et al.
Publicado: (2012) -
Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients
por: Yang, Haitang, et al.
Publicado: (2021) -
Pharmaco-Immunomodulatory Therapy in COVID-19
por: Rizk, John G., et al.
Publicado: (2020)